• Follow the Money: AI-Powered Drug Discovery, Remote Access Labs

    Bio-IT World | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more.

    Jul 1, 2021

  • The Value Of Lab Data Automation To Facilitate Data-Centric Research

    Bio-IT World | In recent years, scientific research has moved from being process-driven to data-driven. Scientists are inferring the results of experiments by analyzing more data than ever, and it’s clear that companies that own the cleanest, best-annotated data will be the most successful in making ground-breaking discoveries within this paradigm. That said there are still significant challenges to data-driven research.

    Jun 30, 2021

  • Insilico Medicine Nets $225M, Pistoia Alliance Pushes Forward with FAIR, New Products

    Bio-IT World | Colorado researchers publish a new method to increase the utility and equity of large genetic databases, new collaboration for BC Platforms and CareDuchenne, Minnesota Supercomputing Institute joins iRODS, and what’s next for Biogen and Eisai. Plus new products from Benchling, Egnyte, Cytek, Waters, Bruker, and more.

    Jun 29, 2021

  • Data Privacy Is Key to Enabling the Medical Community to Leverage Artificial Intelligence to Its Full Potential

    Bio-IT World | If there’s anything the global pandemic has taught healthcare providers, it is the importance of timely and accurate data analysis and being ready to act on it. Yet these same organizations must move within the bounds of patient rights regulations, both existing and emerging, making it harder to access the data needed for building relevant artificial intelligence (AI) models. One way to get around this constraint is de-identify the data before curating it into one centralized location where it can be used for AI model training.

    Jun 24, 2021

  • Digital Patients Could Help More Drugs Reach Market

    Bio-IT World | Clinical trials employing digital representations of patients and running in parallel with actual clinical trials could soon help researchers understand what separates responders and nonresponders to a drug.

    Jun 22, 2021

  • H3’s Data Centric Approach to Cancer Genomics

    Bio-IT World | Lihua Yu took on the role of President of H3 three years ago; she oversees R&D and corporate development operations. She discusses her career trajectory and how the ideas and technologies fueling precision medicine have evolved since she joined H3.

    Jun 22, 2021